Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GQ1001 |
| Synonyms | |
| Therapy Description |
GQ1001 is an antibody-drug conjugate (ADC) consisting of trastuzumab and DM1 conjugated with a stable linker, which may lead to improved growth inhibition of ERBB2 (HER2)-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2702). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GQ1001 | GQ-1001|GQ 1001|ADC GQ1001 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 | GQ1001 is an antibody-drug conjugate (ADC) consisting of trastuzumab and DM1 conjugated with a stable linker, which may lead to improved growth inhibition of ERBB2 (HER2)-expressing tumors (Cancer Res (2023) 83 (7_Supplement): 2702). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04450732 | Phase I | GQ1001 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | Unknown status | USA | AUS | 1 |